Short Interest in Evotec SE (NASDAQ:EVO) Rises By 42.0%

Evotec SE (NASDAQ:EVO) was the target of a significant increase in short interest during the month of September. As of September 15th, there was short interest totalling 271,800 shares, an increase of 42.0% from the August 31st total of 191,400 shares. Based on an average daily volume of 83,900 shares, the days-to-cover ratio is presently 3.2 days. Approximately 0.1% of the company’s shares are short sold.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft lowered Evotec from a “hold” rating to a “sell” rating in a research note on Thursday, August 8th. HC Wainwright lowered their price objective on Evotec from $11.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, August 15th. Finally, Morgan Stanley downgraded Evotec from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $15.00 to $6.00 in a research note on Monday, July 29th.

Hedge Funds Weigh In On Evotec

A number of hedge funds have recently made changes to their positions in EVO. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Evotec in the 2nd quarter valued at about $87,000. Cetera Advisors LLC bought a new stake in shares of Evotec in the 1st quarter worth approximately $188,000. DCF Advisers LLC raised its holdings in shares of Evotec by 140.5% in the 2nd quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock worth $552,000 after purchasing an additional 67,156 shares in the last quarter. Optiver Holding B.V. raised its holdings in shares of Evotec by 643.1% during the fourth quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock valued at $945,000 after acquiring an additional 69,936 shares during the period. Finally, Mubadala Investment Co PJSC acquired a new stake in shares of Evotec during the fourth quarter valued at approximately $53,931,000. Institutional investors and hedge funds own 5.81% of the company’s stock.

Evotec Stock Up 2.3 %

Evotec stock traded up $0.08 during mid-day trading on Friday, reaching $3.57. The company had a trading volume of 116,721 shares, compared to its average volume of 107,509. Evotec has a 1 year low of $2.85 and a 1 year high of $12.00. The company has a current ratio of 1.83, a quick ratio of 1.73 and a debt-to-equity ratio of 0.42. The stock’s 50-day simple moving average is $3.68 and its 200-day simple moving average is $5.02.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.